| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
In the present study, we report the development of r9-CatB-p14MIS peptide which enhances the antitumor effects in many cancer cells. The r9-CatB-p14MIS peptide translocated effectively to the mitochondria and triggered a reduction of mitochondrial membrane potential compared with prototype p14ARF peptides. In addition, cancer cells exhibited different levels of sensitivity to r9-Cat B-p14MIS peptide and the antitumor effects by the peptide were dependent on the expression of endogenous mitochondrial p14ARF, ATPAF1 (F1-ATPase assembly protein) and the magnitude of mitochondrial membrane potential. Furthermore, delivery of r9-CatB-p14MIS to the xenografted pancreatic tumor in mice suppressed tumor volume and cellular proliferation. These results suggested that r9-CatB-p14MIS was useful as novel antitumor molecule.
|
